GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
Open original sourceLoading market dashboard
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
Open original source